Skip to main content

Adoptive immunotherapy for malignant glioma.

Publication ,  Journal Article
Mitchell, DA; Fecci, PE; Sampson, JH
Published in: Cancer J
2003

Despite remarkable advancements in imaging modalities and treatment options available to patients diagnosed with malignant brain tumors, the prognosis for those with high-grade lesions remains poor. The imprecise mechanisms of currently available treatments to manage these tumors do not spare damage to the normal surrounding brain and often result in major cognitive and motor deficits. Immunotherapy holds the promise of offering a potent, yet targeted, treatment to patients with brain tumors, with the potential to eradicate the malignant tumor cells without damaging normal tissues. The T cells of the immune system are uniquely capable of recognizing the altered protein expression patterns within tumor cells and mediating their destruction through a variety of effector mechanisms. Adoptive T-cell therapy is an attempt to harness and amplify the tumor-eradicating capacity of a patients' own T cells and then return these effectors to the patient in such a state that they effectively eliminate residual tumor. Although this approach is not new to the field of tumor immunology, new advancements in our understanding of T-cell activation and function and breakthroughs in tumor antigen discovery hold great promise for the translation of this modality into a clinical success.

Duke Scholars

Published In

Cancer J

DOI

ISSN

1528-9117

Publication Date

2003

Volume

9

Issue

3

Start / End Page

157 / 166

Location

United States

Related Subject Headings

  • Tumor Necrosis Factor Receptor Superfamily, Member 7
  • T-Lymphocytes
  • Oncology & Carcinogenesis
  • Lymphocytes, Tumor-Infiltrating
  • Lymph Nodes
  • Killer Cells, Lymphokine-Activated
  • Immunotherapy, Adoptive
  • Immunotherapy, Active
  • Humans
  • Glioma
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mitchell, D. A., Fecci, P. E., & Sampson, J. H. (2003). Adoptive immunotherapy for malignant glioma. Cancer J, 9(3), 157–166. https://doi.org/10.1097/00130404-200305000-00004
Mitchell, Duane A., Peter E. Fecci, and John H. Sampson. “Adoptive immunotherapy for malignant glioma.Cancer J 9, no. 3 (2003): 157–66. https://doi.org/10.1097/00130404-200305000-00004.
Mitchell DA, Fecci PE, Sampson JH. Adoptive immunotherapy for malignant glioma. Cancer J. 2003;9(3):157–66.
Mitchell, Duane A., et al. “Adoptive immunotherapy for malignant glioma.Cancer J, vol. 9, no. 3, 2003, pp. 157–66. Pubmed, doi:10.1097/00130404-200305000-00004.
Mitchell DA, Fecci PE, Sampson JH. Adoptive immunotherapy for malignant glioma. Cancer J. 2003;9(3):157–166.

Published In

Cancer J

DOI

ISSN

1528-9117

Publication Date

2003

Volume

9

Issue

3

Start / End Page

157 / 166

Location

United States

Related Subject Headings

  • Tumor Necrosis Factor Receptor Superfamily, Member 7
  • T-Lymphocytes
  • Oncology & Carcinogenesis
  • Lymphocytes, Tumor-Infiltrating
  • Lymph Nodes
  • Killer Cells, Lymphokine-Activated
  • Immunotherapy, Adoptive
  • Immunotherapy, Active
  • Humans
  • Glioma